BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer

Inhibidor de BRAF; Binimetinib; Cáncer de colon

Detalles Bibliográficos
Autores: Ros Montañá, Fco. Javier, Baraibar Argota, Iosune, Sardo, Emilia, Mulet Margalef, Núria, Salva Ballabrera, Francesc, Argilés Martinez, Guillem, Ciardiello, Davide, Tabernero Caturla, Josep, Elez Fernandez, Mª Elena, Martini, Giulia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/7159
Acceso en línea:https://hdl.handle.net/11351/7159
Access Level:acceso abierto
Palabra clave:Còlon - Càncer - Tractament
Recte - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
id ES_ffbf60ab9b76b8a082decfe790cffe4d
oai_identifier_str oai:scientiasalut.gencat.cat:11351/7159
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
title BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
spellingShingle BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros Montañá, Fco. Javier
Còlon - Càncer - Tractament
Recte - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
title_short BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
title_full BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
title_fullStr BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
title_full_unstemmed BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
title_sort BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
dc.creator.none.fl_str_mv Ros Montañá, Fco. Javier
Baraibar Argota, Iosune
Sardo, Emilia
Mulet Margalef, Núria
Salva Ballabrera, Francesc
Argilés Martinez, Guillem
Ciardiello, Davide
Tabernero Caturla, Josep
Elez Fernandez, Mª Elena
Martini, Giulia
author Ros Montañá, Fco. Javier
author_facet Ros Montañá, Fco. Javier
Baraibar Argota, Iosune
Sardo, Emilia
Mulet Margalef, Núria
Salva Ballabrera, Francesc
Argilés Martinez, Guillem
Ciardiello, Davide
Tabernero Caturla, Josep
Elez Fernandez, Mª Elena
Martini, Giulia
author_role author
author2 Baraibar Argota, Iosune
Sardo, Emilia
Mulet Margalef, Núria
Salva Ballabrera, Francesc
Argilés Martinez, Guillem
Ciardiello, Davide
Tabernero Caturla, Josep
Elez Fernandez, Mª Elena
Martini, Giulia
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Ros J, Baraibar I, Salvà F, Argilés G, Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sardo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mulet N] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medical Oncology, Institut Català d’Oncologia, Barcelona, Spain. [Martini G, Ciardiello D] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Caserta, Campania, Italy. [Tabernero J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. UVic-UCC, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Còlon - Càncer - Tractament
Recte - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
topic Còlon - Càncer - Tractament
Recte - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
description Inhibidor de BRAF; Binimetinib; Cáncer de colon
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/7159
url https://hdl.handle.net/11351/7159
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Therapeutic Advances in Medical Oncology;13
https://doi.org/10.1177/1758835921992974
info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00947
info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00968
dc.rights.none.fl_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425802073866240
spelling BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancerRos Montañá, Fco. JavierBaraibar Argota, IosuneSardo, EmiliaMulet Margalef, NúriaSalva Ballabrera, FrancescArgilés Martinez, GuillemCiardiello, DavideTabernero Caturla, JosepElez Fernandez, Mª ElenaMartini, GiuliaCòlon - Càncer - TractamentRecte - Càncer - TractamentMetàstasiDISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyDISEASES::Neoplasms::Neoplastic Processes::Neoplasm MetastasisENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectalesOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásicaInhibidor de BRAF; Binimetinib; Cáncer de colonBRAF inhibitor; Binimetinib; Colon cancerInhibidor de BRAF; Binimetinib; Càncer de còlonIntroduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characterized by a poor prognosis and dismal median survival. Following successful outcomes with BRAF inhibition in BRAF mutant metastatic melanoma, this approach was evaluated in metastatic colorectal cancer (mCRC). The development and combination of targeted therapies against multiple signaling pathways has proved particularly successful, with improved survival and response rates. Areas covered: This review addresses the development of therapeutic strategies with inhibitors targeting MAPK/ERK and EGFR signaling in BRAF V600E mutated mCRC, focusing on encorafenib, binimetinib and cetuximab. A pharmacological and clinical review of these drugs and the therapeutic approaches behind their optimization are presented. Expert opinion: Exploiting knowledge of the mechanisms of resistance to BRAF inhibitors has been crucial to developing effective therapeutic strategies in BRAF-V600E mutant mCRC. The BEACON trial is a successful example of this approach, using encorafenib and cetuximab with or without binimetinib in patients with previously treated BRAF V600E mutant mCRC, showing an impressive improvement in clinical outcomes and tolerable toxicity compared with chemotherapy, establishing a new standard of care in this setting.The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI17/00947, PI20/00968) and from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635342.SAGE PublicationsInstitut Català de la Salut[Ros J, Baraibar I, Salvà F, Argilés G, Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sardo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mulet N] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medical Oncology, Institut Català d’Oncologia, Barcelona, Spain. [Martini G, Ciardiello D] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Caserta, Campania, Italy. [Tabernero J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. UVic-UCC, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/7159Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésTherapeutic Advances in Medical Oncology;13https://doi.org/10.1177/1758835921992974info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00947info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00968Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/71592026-06-12T09:38:37Z
score 15,81155

Similares en LA Referencia